Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Benzoyl peroxide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
–
–
–
–
Mild Mild
□
Moderate
Moderate
Severe
✓ X X
e Acnecide Face Gel Do not use Acnecide Face Gel if you: a rash or itching.
Acnecide Face Gel Always use this medicine exactly as described in this leaflet. Check with your doctor or pharmacist if you are not sure. Benzoyl peroxide may cause irritation. a day if tolerated. You should therefore start by using this product on alternate days to minimise this risk and then gradually increase the frequency of use up to twice a If you experience any severe skin irritation stop using the product. If this irritation does not improve after stopping, please consult your doctor or pharmacist.
Galderma Laboratories Product code: P201314-0 Product description: ACNECIDE 2.5 GEL Market: GB Article: Leaflet Font size: 9 9 pt Flat size: 180×315 Fold size: 180×26,25 Pharmacode: 2504 GRAPHIC DESIGNER: Marc TRAMOY
INDUSTRIALIZATION DEPARTMENT INDUSTRIALIZATTON
–
ALBY-SUR-CHERAN-FRANCE Galderma – 74540 AlBY-SUR-CHlRAN LABORATOIRES FRANCE lABORATOIRES GALDERMA – l./, Ga/derma –
GALDERMA
Printing Colors CYAN MAGENTA JAUNI NOIR
DIELINES
NOTICE VERSO 180×315 PLAN n° MT.09.DRA.0352.R02.2 Use in adults and adolescents aged 12 years and over Unless your doctor or pharmacist has told you otherwise: — Wash the affected area with aa mild skin cleanser and water, and gently pat your skin dry. Apply the gel in aa thin layer to all the affected areas of the face. Avoid contact with sensitive areas such as eyes, mouth, nose lining and neck. -Apply
Like all medicines, this medicine can cause side effects, although not everybody gets them. Severe allergic reactions have occurred in aasmall number of people but their frequency is not known. STOP using Acnecide Face Gel and tell your doctor immediately if you develop aasevere allergic reaction. Signs of severe allergic reactions may include:
Acnecide Face Gel
What Acnecide Face Gel contains The active substance is benzoyl peroxide. Every gram of Acnecide Face Gel contains 25 mg (2.5%) benzoyl peroxide (as hydrous benzoyl peroxide). The other ingredients are docusate sodium, disodium edetate, poloxamer, carbomer, propylene glycol (E1520), acrylates copolymer, glycerol, colloidal anhydrous silica, purified water and sodium hydroxide to adjust the pH. What Acnecide Face Gel looks like and contents of the pack Acnecide Face Gel is aawhite to off-white gel. It is available in tubes of 15 g. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Galderma (UK) Limited, Evergreen House North, Grafton Place, London, NW1 2DX, UK Tel: 0300 3035674 E-mail: [email protected] PL 10590/0073 Montdésir, 74540 Alby-sur-Cheran, Alby-sur-Chéran, France. Manufacturer: Laboratoires Galderma, ZI- Montdesir, This leaflet was last revised in March 2025. 7. General advice for people with acne and do da not thie can ac this tan mich nat pick or squeeze your ennte ran make mala them tham worse. spots as much and •e© Try not to touch your face too
–
–
–
a
may
–
GALDERMA Galderma Laboratories Product code: P201314-0 Product description: ACNECIDE 2.5 GEL Market: GB Article: Leaflet For size: 99 pt Font Flat size: 180×315 Fold size: 180×26,25 Pharmacode: 2504 GRAPHIC DESIGNER: Marc TRAMOY
INDUSTRIALIZATION DEPARTMENT
Galderma 74540 ALBY-SUR-CHERAN LABORATOIRES lAB0RATOIRE5 GALDERMA -l./, GaldermaALBY-SUR-CHfRAN- FRANCE –
–
–
Printing Colors NOIR
GALDERMA GALDERMA.——:::-"l"':c-=-c=—-~ DIELINES
P201314-0
–
Acnecide Face 2.5% w/w Gel comes as gel. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Acnecide Face 2.5% w/w Gel is benzoyl peroxide.
Medicines with the same active substance, strength and form include: Acnecide 10% w/w Gel, Acnecide 5% w/w Gel, Acnecide Face 5% w/w Gel. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Acnecide Face 2.5% w/w Gel, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Topical therapy for the treatment of mild acne affecting the face, when comedones (blackheads and whiteheads) predominate, and there are few or no papules and pustules (acne spots and pimples) and no inflamed spots.
Acnecide Face Gel is indicated in adults and adolescents aged 12 years and over.
Posology:
Adults and adolescents aged 12 years and over
Before each application, the skin should be cleaned and dried carefully. When first used, apply in a thin layer once daily to the acne-affected areas before going to bed. After 2-3 days, if the treatment is well tolerated, the frequency of application can be increased to twice daily, in the morning and evening. Persons with sensitive skin should apply the gel once daily before going to bed. The extent of any drying or peeling may be adjusted by modifying the dosage schedule (see section 4.4).
It is recommended to initiate the treatment with benzoyl peroxide 2.5 or 5% gel. In case adequate results are not achieved with the 5% gel and the 5% gel is well tolerated, the treatment with benzoyl peroxide 10% gel may be started.
Paediatric population:
The safety and efficacy of Acnecide Face Gel in children aged less than 12 years have not been established. No data are available.
Method of administration:
Acnecide is indicated for external (dermatological) use only.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
For external use only.
This product is not suitable for individuals with severe acne (characterised by large numbers of inflamed spots on the face or the presence of nodules and cysts), moderate acne (characterised by papules and pustules) or previous scarring from acne, who should seek treatment advice from a doctor.
Individuals with extensive acne lesions affecting other areas (e.g. the chest shoulders and back), which they want to treat, should consult their pharmacist or doctor. These lesions are often more difficult to treat and topical treatments may not be appropriate if they are widespread.
Individuals with mild acne who are particularly concerned by their condition should consult their doctor.
Acnecide Face Gel may cause swelling and blistering of the skin. If any of these symptoms occur, this medication has to be discontinued.
A mild burning sensation will probably be felt on first application and some reddening and peeling of the skin will occur within a few days. During the first weeks of treatment a sudden increase in peeling will occur in most people. This is not harmful and will normally subside within a day or two if treatment is temporarily discontinued. Adjunctive use of moisturizers can help to limit the potential for skin irritation.
If severe irritation occurs, individuals should temporarily discontinue use until the irritation subsides. If treatment is restarted, the product should be applied less frequently (i.e. once a day instead of twice daily or on alternate days instead of once a day). If severe irritation occurs again after treatment is restarted, discontinue use altogether.
Excessive application will not improve efficacy, but may increase the risk of skin irritation.
In the event of scarring following initial treatment with Acnecide Face Gel, treatment should be discontinued and advice should be sought from a doctor.
Benzoyl peroxide gel should not come into contact with the eyes, mouth, angles of the nose or mucous membranes. If the preparation enters the eye, wash thoroughly with water. Acnecide Face Gel should not be applied to the neck and other sensitive areas (around the eyes and mouth, angles of the nose and mucous membranes).
Since Acnecide Face Gel may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sunlight or UV radiation should be avoided. When strong sunlight cannot be avoided, individuals should use a sun-protection product with a protection factor of at least SPF 30 and UVA protection and wear protective clothing.
Contact with any coloured material including hair and dyed fabrics may result in bleaching or discoloration.
Due to the risk of sensitisation, benzoyl peroxide gel should not be applied on damaged skin.
Acnecide Face Gel should not be used in conjunction with other benzoyl peroxide preparations (including other Acnecide products), nor with any other topical or systemic treatment(s) for acne except under medical supervision.
Individuals should cease use and seek medical advice if their condition deteriorates despite therapy, or in cases of a lack of response after use for 12 weeks.
This medicinal product contains 40 mg of propylene glycol (E1520) in each gram, which is equivalent to 4.0% w/w. It may cause skin irritation.
No interaction studies have been performed; however, drugs with desquamative, irritant and drying effects should not be used concurrently with Acnecide Face gel.
Pregnancy
There is no safety concern relating to the effects of cutaneously applied benzoyl peroxide on teratogenicity, embryotoxicity, or peri- and post- natal development from animal data. In widespread clinical use for the cutaneous treatment of acne vulgaris, at concentrations up to 10% w/w for several decades, benzoyl peroxide has never been associated with such effects. Acnecide should only be used by a pregnant woman under medical supervision.
Breast-feeding
It is unknown whether benzoyl peroxide/metabolites are excreted in human milk. A risk to the new-borns/infants cannot be excluded. Caution should be exercised when benzoyl peroxide is administered to a nursing woman and the preparation should not be applied on the chest to avoid accidental transfer to the infant. Acnecide Face Gel should only be used by a nursing woman under medical supervision.
Fertility
There is no safety concern relating to the effects of cutaneously applied benzoyl peroxide on reproductive function or fertility from animal data. In widespread clinical use for the cutaneous treatment of acne vulgaris, at concentrations up to 10% w/w for several decades, benzoyl peroxide has never been associated with such effects.
Acnecide Face Gel has no or negligible influence on the ability to drive and use machines.
The adverse reactions resulting from clinical trials are all skin disorders. They are reversible when treatment is reduced in frequency or discontinued.
The following categories are used to indicate the frequency of occurrence of adverse effects:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥ 1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (frequency cannot be estimated from the available data).
They are presented in the table below:
Skin and subcutaneous tissue disorders
Very common (≥1/10)
Dry skin
Erythema
Skin exfoliation (peeling)
Skin burning sensation
Common (≥1/100 to <1/10)
Pruritus
Pain of skin (pain, stinging),
Skin irritation (irritant contact dermatitis)
Uncommon (≥1/1,000 to <1/100)
Allergic contact dermatitis
Swelling of the face and allergic reactions, including application site hypersensitivity and anaphylaxis (frequency not known) have been reported during post-marketing surveillance.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website at: https://yellowcard.mhra.gov.uk - or search for MHRA Yellow Card in the Google Play or Apple App Store.
Acnecide Face Gel is a preparation indicated for topical treatment only. If the medication is applied excessively, no more rapid or better results will be obtained and severe irritation might develop. In this event, treatment must be discontinued and appropriate symptomatic therapy including the use of moisturisers, should be instituted.
Ask anything about Acnecide Face 2.5% w/w Gel. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.